SG Americas Securities LLC Acquires New Position in Beta Bionics, Inc. $BBNX

Key Points

• SG Americas Securities opened a new position in Beta Bionics of 150,277 shares (~$4.58M) in Q4, and several other institutions boosted stakes — notably Vanguard added ~1.51M shares during the period.
• Insiders have been selling recently: CFO Stephen Feider sold 20,000 shares and Mike Mensinger 7,800, with a total of 34,705 insider shares sold (~$945,653) in the last three months.
• Wall Street consensus is a Moderate Buy with an average target of $23.20, yet the stock traded at $10.01 (52-week range $8.89–$32.71) after reporting EPS of -$0.30 that beat estimates, highlighting mixed fundamentals and high volatility.

SG Americas Securities LLC acquired a new position in shares of Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 150,277 shares of the company's stock, valued at approximately $4,579,000. SG Americas Securities LLC owned about 0.34% of Beta Bionics at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Eventide Asset Management LLC boosted its holdings in Beta Bionics by 0.5% in the 3rd quarter. Eventide Asset Management LLC now owns 4,957,252 shares of the company's stock valued at $98,500,000 after purchasing an additional 24,901 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of Beta Bionics by 2.6% during the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company's stock worth $85,718,000 after buying an additional 110,000 shares during the last quarter. Soleus Capital Management L.P. raised its position in shares of Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company's stock valued at $55,622,000 after buying an additional 424,817 shares during the period. Sands Capital Alternatives LLC raised its position in shares of Beta Bionics by 15.0% during the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company's stock valued at $51,981,000 after buying an additional 466,331 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Beta Bionics by 213.5% in the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock valued at $44,036,000 after acquiring an additional 1,509,217 shares during the last quarter.

Insider Activity

In related news, CFO Stephen Feider sold 20,000 shares of the firm's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the transaction, the chief financial officer directly owned 42,614 shares in the company, valued at $1,258,391.42. This trade represents a 31.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mike Mensinger sold 7,800 shares of Beta Bionics stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.61, for a total value of $230,958.00. Following the completion of the transaction, the insider directly owned 82,952 shares of the company's stock, valued at approximately $2,456,208.72. This represents a 8.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 34,705 shares of company stock worth $945,653.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BBNX. Stifel Nicolaus lowered their price objective on Beta Bionics from $25.00 to $22.00 and set a "buy" rating for the company in a research report on Wednesday, February 18th. Wall Street Zen lowered Beta Bionics from a "hold" rating to a "sell" rating in a research note on Sunday. Lake Street Capital set a $20.00 price target on Beta Bionics in a report on Wednesday, February 18th. Truist Financial cut their price objective on Beta Bionics from $37.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, February 2nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Beta Bionics in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Beta Bionics has a consensus rating of "Moderate Buy" and an average target price of $23.20.

Beta Bionics Stock Performance

Beta Bionics stock opened at $10.01 on Thursday. The company has a market capitalization of $444.24 million, a PE ratio of -5.13 and a beta of 5.03. Beta Bionics, Inc. has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The firm has a 50 day moving average price of $12.59 and a 200 day moving average price of $21.07.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.The company had revenue of $32.12 million for the quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.